taa05
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2021 (NCT05017883)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor-type tyrosine-protein kinase FLT3Immunity, passive
FLT3 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05445011 | Phase 1 | Jun 14, 2022 | Huazhong University of Science and Technology, PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| NCT05017883 | N/A | Jul 1, 2021 | Anhui Medical University, Government of China, PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | For profit | 2 | 1 | 2 | 2021 |
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Government of China | Government | 1 | 0 | 1 | 2021 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1